Important aspects of Toll-like receptors, ligands and their signaling pathways, Inflammation Research, vol.125, issue.Suppl 3, pp.791-808, 2010. ,
DOI : 10.1007/s00011-010-0208-2
TLR based therapeutics, Current Opinion in Pharmacology, vol.11, issue.4, pp.404-411 ,
DOI : 10.1016/j.coph.2011.03.004
Toll-like receptor 9 (TLR9) agonists in the treatment of cancer, Oncogene, vol.89, issue.2, pp.161-167, 2008. ,
DOI : 10.1182/blood-2004-03-1190
Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization, Proceedings of the National Academy of Sciences, vol.94, issue.20, pp.9410833-10837, 1997. ,
DOI : 10.1073/pnas.94.20.10833
Human Peripheral Blood Cells Differentially Recognize and Respond to Two Distinct CpG Motifs, The Journal of Immunology, vol.166, issue.4, pp.2372-2377, 2001. ,
DOI : 10.4049/jimmunol.166.4.2372
Mechanism and Function of a Newly Identified CpG DNA Motif in Human Primary B Cells, The Journal of Immunology, vol.164, issue.2, pp.944-953, 2000. ,
DOI : 10.4049/jimmunol.164.2.944
CpG motifs in bacterial DNA trigger direct B-cell activation, Nature, vol.374, issue.6522, pp.374546-549, 1995. ,
DOI : 10.1038/374546a0
Involvement of heat shock protein (Hsp) 90 beta but not Hsp90 alpha in antiapoptotic effect of CpG-B oligodeoxynucleotide, J Immunol, issue.10, pp.1786100-6108, 2007. ,
B-Cell Lymphomas Differ in their Responsiveness to CpG Oligodeoxynucleotides, Clinical Cancer Research, vol.11, issue.4, pp.1490-1499, 2005. ,
DOI : 10.1158/1078-0432.CCR-04-1890
Toll-like receptor 9 signaling by CpG-B oligodeoxynucleotides induces an apoptotic pathway in human chronic lymphocytic leukemia B cells, Blood, vol.115, issue.24, pp.1155041-5052, 2010. ,
DOI : 10.1182/blood-2009-03-213363
Modulation of malignant B cell activation and apoptosis by bcl-2 antisense ODN and immunostimulatory CpG ODN, J Leukoc Biol, vol.72, issue.1, pp.83-92, 2002. ,
Primary lymphoma of the central nervous system: epidemiology, pathology and current approaches to diagnosis, prognosis and treatment, Leukemia & Lymphoma, vol.110, issue.sup1, pp.43-51, 2008. ,
DOI : 10.1182/blood-2007-10-119099
Murine Models of B-Cell Lymphomas: Promising Tools for Designing Cancer Therapies, Advances in Hematology, vol.9, issue.17, pp.701-704, 2012. ,
DOI : 10.1016/j.biopha.2010.01.004
T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy, Blood, vol.113, issue.15, pp.3546-3552, 2009. ,
DOI : 10.1182/blood-2008-07-170274
The immunobiology and clinical potential of immunostimulatory CpG oligodeoxynucleotides, J Leukoc Biol, vol.68, issue.4, pp.455-463, 2000. ,
Lymphoma Immunotherapy with CpG Oligodeoxynucleotides Requires TLR9 Either in the Host or in the Tumor Itself, The Journal of Immunology, vol.179, issue.4, pp.2493-2500, 2007. ,
DOI : 10.4049/jimmunol.179.4.2493
CpG oligodeoxynucleotides as immunotherapy in cancer, Update on Cancer Therapeutics, vol.3, issue.1, pp.27-32, 2008. ,
DOI : 10.1016/j.uct.2007.11.003
CpG oligodeoxynucleotide-based therapy of lymphoid malignancies, Advanced Drug Delivery Reviews, vol.61, issue.3, pp.263-267, 2009. ,
DOI : 10.1016/j.addr.2008.12.006
What is immune privilege (not)? Trends Immunol, pp.12-18, 2007. ,